HPV-Impfung bei Kindern, Jugendlichen und jungen Erwachsenen

Ulrike Wieland

doi:10.1055/a-2089-0722

Kinder- und Jugendmedizin, Inhaltsverzeichnis

Kinder- und Jugendmedizin 2023; 23(03): 192-199
DOI: 10.1055/a-2089-0722

Schwerpunkt

HPV-Impfung bei Kindern, Jugendlichen und jungen Erwachsenen

HPV vaccination in children, adolescents, and young adults

Ulrike Wieland∗

¹Uniklinik Köln, Institut für Virologie, Nationales Referenzzentrum für Papillom- und Polyomaviren

› Institutsangaben

Abstract

ZUSAMMENFASSUNG

Neben gutartigen Kondylomen zählen Krebsvorstufen von Zervix, Vulva, Vagina, Anus und Penis sowie die entsprechenden Karzinome zu den HPV-bedingten Erkrankungen. In den letzten Jahrzehnten haben HPV-assoziierte Oropharynxkarzinome zugenommen, vor allem bei Männern. Insgesamt werden 4–5 % aller Krebserkrankungen durch HPV verursacht. In allen HPV-bedingten Karzinomen ist HPV16 der häufigste HPV-Typ. Kondylome und die rezidivierende Larynxpapillomatose (RLP) werden durch HPV6 und 11 ausgelöst. Die meisten HPV-assoziierten Erkrankungen können durch prophylaktische HPV-Impfung verhindert werden, wobei ein junges Impfalter bzw. HPV-Naivität entscheidend sind. In Ländern mit hohen HPV-Impfraten bei Kindern und Jugendlichen nehmen nicht nur Kondylome, sondern auch das Zervixkarzinom und seine Vorstufen drastisch ab. In Australien und den USA wird ein deutlicher Rückgang der juvenilen RLP beobachtet, weil geimpfte Mütter vor HPV6/11 geschützt sind. Metaanalysen kommen zu dem Schluss, dass die Off-Label-HPV-Impfung als adjuvante Therapie bei RLP einen Nutzen haben könnte, aber weitere Studien notwendig sind. Die WHO strebt die Elimination des Zervixkarzinoms an. Dazu müssen bei Mädchen bis zum 15. Lebensjahr HPV-Impfraten von 90 % in allen Ländern erreicht werden. Da in Deutschland die HPV-Impfquote bei 15-jährigen Mädchen nur bei 54 % liegt (Jungen 26,5 %), sind weitere Anstrengungen zur Erhöhung der Impfraten notwendig.

ABSTRACT

HPV-induced diseases comprise benign genital warts, precancerous lesions of the cervix, vulva, vagina, anus, and penis as well as the corresponding carcinomas. In recent decades, HPV-associated oropharyngeal cancer has increased, especially in men. Overall, 4–5 % of all human cancers are caused by HPV. In all HPV-related cancers, HPV16 is the most common HPV-type. Genital warts and recurrent respiratory papillomatosis (RRP) are caused by HPV6 and 11. Most HPV-associated diseases are preventable by prophylactic HPV vaccination, with young age at vaccination respectively HPV naivety being critical. In countries with high HPV vaccination rates in children and adolescents, both genital warts and cervical cancer and its precursors have decreased dramatically. In Australia and the United States, a significant decline in juvenile-onset RRP has been observed since vaccinated mothers are protected from HPV6/11. Meta-analyses conclude that off-label HPV vaccination may be a beneficial adjuvant treatment for RRP, but further studies are needed. WHO aims to eliminate cervical cancer. This will require HPV vaccination rates of 90 % in girls by the age of 15 in all countries. Since the HPV vaccination rate in 15-year-old girls in Germany is only 54 % (boys 26.5 %), further efforts to increase vaccination rates are needed.

Schlüsselwörter

Humane Papillomviren (HPV) - Impfung - Prophylaxe

Keywords

Human papillomavirus (HPV) - vaccination - prophylaxis

Volltext

Referenzen

Literatur
1 Bernard HU. Taxonomy and phylogeny of papillomaviruses: an overview and recent developments. Infect Genet Evol 2013; 18: 357-361
2 Bouvard V, Baan R, Straif K. et al A review of human carcinogens – Part B: biological agents. Lancet Oncol 2009; 10: 321-322
3 Muñoz N, Bosch FX, de Sanjosé S. et al Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-527
4 Chesson HW, Dunne EF, Hariri S. et al The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis 2014; 41: 660-664
5 Giuliano AR, Lee JH, Fulp W. et al Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-940
6 Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis 2018; 18: 198-206
7 Sand FL, Munk C, Frederiksen K. et al Risk of CIN3 or worse with persistence of 13 individual oncogenic HPV types. Int J Cancer 2019; 144: 1975-1982
8 Schiffman M, Castle PE, Jeronimo J. et al Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907
9 Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117: S5-10
10 Weaver B, Shew M, Qadadri B. et al Natural history of multiple human papillomavirus infections in female adolescents with prolonged follow-up. J Adolesc Health 2011; 48: 473-480
11 de Martel C, Georges D, Bray F. et al Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health 2020; 08: e180-e190
12 Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012; 10: 681-692
13 Guo T, Eisele DW, Fakhry C. The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 2016; 122: 231-2323
14 Olesen TB, Sand FL, Rasmussen CL. et al Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol 2019; 20: 145-158
15 Singh D, Vignat J, Lorenzoni V. et al Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 2023; 11: e197-e206
16 de Sanjose S, Quint WG, Alemany L. et al Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-1056
17 Haeggblom L, Ramqvist T, Tommasino M. et al Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Res 2017; 04: 1
18 Ndiaye C, Mena M, Alemany L. et al HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol 2014; 15: 1319-1331
19 Tota JE, Best AF, Zumsteg ZS. et al Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals. J Clin Oncol 2019; 37: 1538-546
20 Van Dyne EA, Henley SJ, Saraiya M. et al Trends in Human Papillomavirus-Associated Cancers – United States, 1999–2015. MMWR Morb Mortal Wkly Rep 2018; 67: 918-924
21 Wittekindt C, Wagner S, Bushnak A. et al Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus. Cancer Prev Res (Phila) 2019; 12: 375-382
22 Senkomago V, Henley SJ, Thomas CC. et al Human Papillomavirus-Attributable Cancers – United States, 2012–2016. MMWR Morb Mortal Wkly Rep 2019; 68: 724-728
23 De Vuyst H, Clifford GM, Nascimento MC. et al Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 162-1636
24 RKI. Krebs in Deutschland für 2017/2018; 2021. https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2021/krebs_in_deutschland_2021.pdf;jsessionid=5D5FAC564981322E54354200886090EE.internet051?__blob=publicationFile Stand: 12.5.2023
25 Gredner T, Behrens G, Stock C. et al Cancers Due to Infection and Selected Environmental Factors. Dtsch Arztebl Int 2018; 115: 586-593
26 Hartwig S, St Guily JL, Dominiak-Felden G. et al Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe. Infect Agent Cancer 2017; 12: 19
27 Kraut AA, Schink T, Schulze-Rath R. et al Incidence of anogenital warts in Germany: a population-based cohort study. BMC Infect Dis 2010; 10: 360
28 Patel H, Wagner M, Singhal P. et al Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13: 39
29 Komloš KF, Kocjan BJ, Košorok P. et al Tumor-specific and gender-specific pre-vaccination distribution of human papillomavirus types 6 and 11 in anogenital warts and laryngeal papillomas: a study on 574 tissue specimens. J Med Virol 2012; 84: 1233-1241
30 Wieland U, Kreuter A. Genital warts in HIV-infected individuals]. Hautarzt 2017; 68: 192-198
31 Wikström A, Vassilaki I, Hedblad MA. et al The spectrum of genital human papillomavirus infection among men attending a Swedish sexually-transmitted infections clinic: human papillomavirus typing and clinical presentation of histopathologically benign lesions. Acta Derm Venereol 2013; 93: 223-227
32 Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: A 2020 perspective. Laryngoscope Investig Otolaryngol 2021; 06: 340-345
33 Novakovic D, Cheng ATL, Zurynski Y. et al A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program. J Infect Dis 2018; 217: 208-212
34 Rosenberg T, Philipsen BB, Mehlum CS. et al Therapeutic Use of the Human Papillomavirus Vaccine on Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-Analysis. J Infect Dis 2019; 219: 1016-1025
35 Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine 2018; 36: 476-4773
36 Schiller JT, Müller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 2015; 16: e217-225
37 MSD. Fachinformation GARDASIL9. Oktober 2022
38 GSK. Fachinformation Cervarix. Oktober 2021
39 FDA. Gardasil 9. Human Papillomavirus 9-valent Vaccine, Recombinant; 2023. https://www.fda.gov/vaccines-blood-biologics/vaccines/gardasil-9 Stand: 12.5.2023
40 Castellsagué X, Giuliano AR, Goldstone S. et al Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine 2015; 33: 6892-6901
41 Iversen OE, Miranda MJ, Ulied A. et al Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. Jama 2016; 316: 2411-2421
42 Van Damme P, Meijer C, Kieninger D. et al A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine 2016; 34: 4205-4212
43 Van Damme P, Olsson SE, Block S. et al Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics 2015; 136: e28-39
44 Arbyn M, Xu L, Simoens C. et al Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018; 05: Cd009069
45 Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 (Suppl. 05) F123-138
46 Oberle UK-S. B. Sicherheit der Impfung gegen humane Papillomviren (HPV). Bulletin zur Arzneimittelsicherheit 2018; 03: 17-23
47 Ali H, Donovan B, Wand H. et al Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Bmj 2013; 346: f2032
48 Castle PE, Maza M. Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect 2016; 144: 449-468
49 Chow EPF, Carter A, Vickers T. et al Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004–18. Lancet Infect Dis 2021; 21: 1747-1756
50 Chow EPF, Tabrizi SN, Fairley CK. et al Prevalence of human papillomavirus in young men who have sex with men after the implementation of gender-neutral HPV vaccination: a repeated cross-sectional study. Lancet Infect Dis 2021; 21: 1448-1457
51 Drolet M, Benard E, Boily MC. et al Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2015; 15: 565-580
52 Falcaro M, Castañon A, Ndlela B. et al The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study. Lancet 2021; 398: 2084-2092
53 Giuliano AR, Palefsky JM, Goldstone S. et al Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med 2011; 364: 401-411
54 Goldstone SE, Giuliano AR, Palefsky JM. et al Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2022; 22: 413-425
55 Joura EA, Giuliano AR, Iversen OE. et al A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med 2015; 372: 711-723
56 Orumaa M, Kjaer SK, Dehlendorff C. et al The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity. Vaccine 2020; 38: 1345-1351
57 Palefsky JM, Giuliano AR, Goldstone S. et al HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-1585
58 Wang WV, Kothari S, Skufca J. et al Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Rev Vaccines 2022; 21: 1799-1817
59 Kjaer SK, Nygård M, Sundström K. et al Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine 2020; 23: 100401
60 Schwarz T, Spaczynski M, Kaufmann A. et al Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. Bjog 2015; 122: 107-118
61 Kjaer SK, Dehlendorff C, Belmonte F. et al Real-World Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer. J Natl Cancer Inst 2021; 113: 1329-1335
62 Lei J, Ploner A, Elfström KM. et al HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med 2020; 383: 1340-1348
63 Chaturvedi AK, Graubard BI, Broutian T. et al Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol 2018; 36: 262-267
64 Hirth JM, Chang M, Resto VA. Prevalence of oral human papillomavirus by vaccination status among young adults (18-30years old). Vaccine 2017; 35: 3446-3451
65 Damgacioglu H, Sonawane K, Chhatwal J. et al Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study. Lancet Reg Health Am 2022; 08: 100143
66 Denecke A, Iftner T, Iftner A. et al Significant decline of HPV 6 infection and genital warts despite low HPV vaccination coverage in young women in Germany: a long-term prospective, cohort data analysis. BMC Infect Dis 2021; 21: 634
67 Meites E, Stone L, Amiling R. et al Significant Declines in Juvenile-onset Recurrent Respiratory Papillomatosis Following Human Papillomavirus (HPV) Vaccine Introduction in the United States. Clin Infect Dis 2021; 73: 885-890
68 Hermann JS, Weckx LY, Monteiro Nürmberger J. et al Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2016; 83: 94-98
69 Park I, Carbone S, Preciado D. Systematic review of the use of human papillomavirus vaccine as adjuvant therapy for juvenile-onset recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 2022; 162: 111314
70 Ponduri A, Azmy MC, Axler E. et al The Efficacy of Human Papillomavirus Vaccination as an Adjuvant Therapy in Recurrent Respiratory Papillomatosis. Laryngoscope. 2023
71 Lorentzen CL, Haanen JB, Met Ö. et al Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol 2022; 23: e450-e458
72 RKI Empfehlungen der Ständigen Impfkommission beim Robert Koch-Institut 2023. Epidemiologisches Bulletin 2023; 04: 1-68
73 Gross GE, Werner RN, Avila Valle GL. et al Impfprävention HPV-assoziierter Neoplasien. Evidenz- und konsensbasierte S3-Leitlinie, AWMF-Register Nr.: 082–002. J Dtsch Dermatol Ges 2021; 19: 479-494
74 RKI Impfquoten von Kinderschutzimpfungen in Deutschland. Epidemiologisches Bulletin 2022; 48: 3-25
75 Wähner C, Hübner J, Meisel D. et al Uptake of HPV vaccination among boys after the introduction of gender-neutral HPV vaccination in Germany before and during the COVID-19 pandemic. Infection 2023
76 RKI Einfluss von Schulimpfprogrammen auf die HPV-Impfquote. Epidemiologisches Bulletin 2022; 20: 3-11
77 WHO One-dose Human Papillomavirus (HPV) vaccine offers solid protection against cervical cancer. https://www.who.int/news/item/11-04-2022-one-dose-human-papillomavirus-(hpv)-vaccine-offers-solid-protection-against-cervical-cancer Stand: 12.5.2023
78 Barnabas RV, Brown ER, Onono MA. et al Efficacy of single-dose HPV vaccination among young African women. NEJM Evid 2022; 01: EVIDoa2100056
79 Basu P, Malvi SG, Joshi S. et al Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study. Lancet Oncol 2021; 22: 1518-1529
80 Kreimer AR, Struyf F, Del Rosario-Raymundo MR. et al Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol 2015; 16: 775-786
81 Markowitz LE, Drolet M, Lewis RM. et al Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs. Vaccine 2022; 40: 5413-5432
82 WHO. Cervical Cancer Elimination Initiative. https://www.who.int/initiatives/cervical-cancer-elimination-initiative#cms 2020 Stand: 12.5.2023
83 Sternjakob-Marthaler A, Berkó-Göttel B, Rissland J. et al Human papillomavirus vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates. PLoS One 2022; 17: e0273332
84 RKI Ärztliche Gesundheitsbildung in Schulen zu HPV – ein wichtiger Beitrag zur Steigerung der HPV-Impfmotivation. Epidemiologisches Bulletin 2022; 36: 11-22
85 Wittenberg I, Werner RN, Mikolajczyk R. et al Wie die Impfprävention gefördert werden kann. Perspektiven der Onkologie – Deutsches Ärzteblatt Supplement 2020; 03: 22-25
86 Wieland U, Kreuter A. [Prevention of HPV-induced diseases by prophylactic vaccination]. Hautarzt 2021; 72: 106-113